Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Operating activities
Net loss	$ (67,727)	$ (40,843)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	11,790	6,718
Amortization of deferred commissions	12,433	8,687
Stock-based compensation expense	56,438	43,141
Impairment (gain) on property and equipment, and lease termination	0	(13,783)
Lease exit costs	7,634	0
Other	1,813	(560)
Changes in assets and liabilities:
Trade and other receivables	63,310	50,224
Deferred commissions	(19,983)	(15,785)
Prepaid expenses and other current assets	(2,214)	(7,405)
Other noncurrent assets	(1,404)	(36)
Accounts payable	(2,912)	1,832
Deferred revenue	(57,766)	(39,198)
Accrued expenses and other current liabilities	(4,295)	4,245
Other noncurrent liabilities	6,574	121
Net cash provided by (used in) operating activities	3,691	(2,642)
Investing activities
Purchases of property, equipment and other	(9,774)	(5,234)
Purchase of marketable securities	(139,196)	(76,122)
Maturities of marketable securities	133,473	23,125
Proceeds from sale of marketable securities	1,100	511
Acquisitions, net of cash acquired	(80,372)	(19,540)
Net cash used in investing activities	(94,769)	(77,260)
Financing activities
Proceeds from initial public offering net of issuance costs, underwriters discounts and commissions, and concurrent private placement	0	320,392
Proceeds from Series F convertible preferred stock, net of issuance costs	0	69,848
Proceeds from revolving line of credit	43,000	0
Proceeds from exercise of stock options	41,032	13,018
Proceeds from share purchase plan	10,267	0
Principal payments on capital leases	(2,117)	(1,469)
Repayment of debt assumed in acquisitions and other	(2,139)	(2,297)
Net cash provided by financing activities	90,043	399,492
Effect of exchange rate changes on cash and cash equivalents	(49)	(47)
Net (decrease) increase in cash and cash equivalents	(1,084)	319,543
Cash and cash equivalents at beginning of period	226,866	44,876
Cash and cash equivalents at end of period	225,782	364,419
Supplemental disclosures of cash flow information
Cash paid for interest	652	265
Cash paid for income taxes	656	806
Noncash investing and financing activities
Other receivables related to stock option exercises	1	0
Vesting of early exercised stock options	0	392
Accrued unpaid issuance costs related to initial public offering	0	690
Accrued unpaid capital expenditures	$ 2,111	$ 5,809